Figure 6
28BB-Fab-Tet-z function and inhibition in vivo. (a) Overview of in vivo experiment. NSG mice were injected i.v. with 0.5 × 106 NALM6-FLuc tumor cells. On day 0, mice were randomly assigned based on tumor burden to receive 5 × 106 non-transduced (NT), FMC63-BBz or 28BB-Fab-Tet-z CAR T cells. Groups were further divided with some to receive 0.4 mg minocycline i.p. every 1–2 days, starting either on day 0 or day 3. (b) Bioluminescence radiance (photons/s/cm2/sr) of NALM6-FLuc tumors in mice in select groups. (c) Geometric mean radiance (photons/s/cm2/sr) of NALM6-FLuc cells, in mice in all groups treated with NT, FMC63-BBz (± minocycline) or 28BB-Fab-Tet-z CAR T cells (± minocycline). n = 4 mice per group from 1 experiment. Table shows statistical analysis through one-way ANOVA with multiple comparisons between groups at each time point.
